AUSTIN, Texas, May 28, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has extended their global supply and distribution agreement with EMD Millipore—the Life Science division of Merck KGaA, Darmstadt, Germany. This long-term agreement strengthens the partnership and facilitates development of life science and protein assays by EMD Millipore for Luminex's flexible platform.
"We are very pleased to extend our global supply and distribution agreement with EMD Millipore, a leader in life science and protein research," said
Michael F. Pintek, senior vice president of operations atLuminex. "EMD Millipore's broad selection of protein biomarkers in diverse research areas such as cancer, cell signaling, cellular metabolism, and immunology reflects their leadership in the life science research market. Together we can accelerate the pace of research and advance healthcare for people around the world."
As part of the agreement, EMD Millipore will continue to offer the full range of Luminex's xMAP® systems, including MAGPIX®, Luminex® 100/200™, and FLEXMAP 3D®. Luminex Technology is widely supported and validated across both clinical and life science research markets, with cumulative shipments to date nearing 10,000 total instruments and over 16,000 publications across a broad spectrum of applications.
"EMD Millipore is committed to continue bringing to researchers the largest selection of assays and analytes for Luminex's instrument portfolio," said
John Sweeney, head of life sciences business at EMD Millipore. "This renewal of our partnership with Luminex ensures that EMD Millipore can provide customers with a complete solution for multiplexed protein detection—encompassing assay kits, instruments, software and services—that will support them over the years."
EMD Millipore, a leader in multiplex assay kit development, has continued to push into emerging areas of research and recently announced the availability of MILLIPLEX® map human stem cell pluripotency kits and MILLIPLEX® map kits for cellular metabolism. Compared with traditional biomarker detection techniques such as western blots, these new kits increase assay throughput and specificity. Additionally, EMD Millipore recently released the newest version of their best-in-class multiplex data analysis package, MILLIPLEX® Analyst 5.1 software—one of the most robust data analysis tools available today for Luminex® platform-based multiplexed immunoassays.
About Luminex Corporation
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture—multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies—that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award-winning technology, please visit //www.luminexcorp.com/.
Luminex Investor Contact:
Matthew Scalo, 512.219.8020
Sr. Director Investor Relations
Luminex Media Contact:
Mimi Torrington, 512.219.8020
Director of Marketing Communications
SOURCE Luminex Corporation